Aspen Neuroscience to Present at ISCT Annual Meeting

Aspen Neuroscience is set to showcase its innovative approach to neuron replacement therapy using autologous induced pluripotent stem cells (iPSCs) at the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada. The event will run from May 29 to June 1, 2024, drawing clinicians, researchers, regulators, technologists, and industry partners from around the globe.

The ISCT annual meeting is recognized for highlighting the latest advancements in cell and gene therapy, and Aspen Neuroscience's participation underscores the company's commitment to translating these scientific breakthroughs into practical medical treatments. Damien McDevitt, Ph.D., the Chief Executive Officer of Aspen Neuroscience, expressed enthusiasm about the event, noting that the ISCT community shares Aspen's vision of transforming the potential of cell and gene therapies into safe, effective medications that enhance patient outcomes.

During the ISCT 2024 Translational Pathway Sessions and the main program, Aspen's leading experts will present significant progress in the field of autologous research and development. These sessions will feature Xiaokui Zhang, Ph.D., Chief Scientific Officer, and Kim Raineri, Chief Technology Officer, who will provide insights into their work on ANPD001, Aspen's autologous iPSC-derived neuron replacement therapy. This therapy is currently being tested in a Phase 1/2a clinical trial for Parkinson's disease, aimed at evaluating its safety and efficacy. Additionally, advancements in the manufacturing processes of autologous iPSCs will also be discussed.

Daniel Fremgen, Aspen's Director of Analytical Development, will present on the company's analytical development strategy. His presentation will cover the use of machine learning and genomic models to characterize autologous iPSCs and dopaminergic neuron precursor cells, which are crucial elements of Aspen's therapeutic approach.

Aspen Neuroscience has scheduled several key presentations during the meeting. On Thursday, May 30, and Saturday, June 1, the company will participate in the "iPSCs Signature Series: From Bench to Bedside," a session that aims to bridge the gap between laboratory research and clinical application, highlighting the journey of iPSC-based therapies from initial development to patient treatment.

Headquartered in San Diego, Aspen Neuroscience, Inc. is a private company at the clinical development stage, specializing in autologous regenerative medicine. The company leverages a patient-derived iPSC platform to develop personalized therapies targeting diseases with significant unmet medical needs, beginning with neuron replacement therapies for Parkinson's disease. Aspen's approach combines advanced cell biology techniques with the latest machine learning and genomic technologies to create patient-specific restorative treatments.

Aspen Neuroscience has created a robust platform for developing and optimizing pluripotent-derived cell therapies. This comprehensive platform includes in-house capabilities for bioinformatics, manufacturing, and quality control, ensuring the highest standards in developing innovative medical treatments.

Aspen's participation in the ISCT 2024 meeting reflects its dedication to advancing the field of regenerative medicine and its commitment to improving the lives of patients through cutting-edge scientific research and development.